Cantargia Q2 2026: The Selloff Is Loud, But the MDS Data Is Louder

Cantargia (Nasdaq Stockholm: CANTA) will report its H1 2026 interim results on August 19. The headline won't be dramatic - net sales for a pre-revenue biotech are measured in the low millions of SEK. But the story between the quarter's bookends is anything but quiet.

The stock has arguably baked in a worst-case narrative. The market cap has roughly halved from its end-of-2025 peak of SEK 1.04 billion to around SEK 440 million as of early August. A rights issue in June was poorly subscribed - only about 21% of the offering was taken up by existing shareholders, forcing Cantargia to rely on a Fenja Capital guarantee for the balance. The board also issued 8.7 million warrants to Fenja, adding dilution overhang. Taken together, the cap table expansion and the price decline have the earmarks of an overdone selloff. The question is whether the business underneath has changed enough to justify the damage.

I don't think it has.

The data that matters most isn't in the original Q2 plan. It's the hematological signal that has quietly emerged and forced management to rethink the pipeline's priorities.

The 5-for-5 signal

In April, Cantargia released early results from an investigator-initiated Phase 1b/2a trial at MD Anderson Cancer Center evaluating nadunolimab - the company's IL1RAP-blocking antibody - in combination with azacitidine in high-risk myelodysplastic syndrome (MDS). Five of five evaluable patients achieved complete remission. The sixth patient's evaluation was still pending. The Phase 1b dose-escalation stage is now complete, and the study has moved into the Phase 2a expansion, targeting approximately 40 patients total.

MDS is a group of blood cancers in which the bone marrow fails to produce healthy blood cells. Complete remission - where blood counts return to normal and blast cells in the marrow fall below a defined threshold - is the gold-standard response measure and notoriously difficult to achieve in high-risk patients. A 100% remission rate in even a small cohort is the kind of signal that changes a pipeline's trajectory. It is also the kind of signal that demands a dose of skepticism when the denominator is five.

The sample is undeniably small. That's the real counterpoint. Five patients do not make a registrable program, and hematologists know that early Phase 1b responses in rare blood cancers can look better than they sustain at scale. But the consistency - all five evaluable patients, not one outlier - and the manageable safety profile are enough to justify a formal hematologic program, which management confirmed they've now initiated. The follow-up data expected later in 2026, including any readout from the broader Phase 2a cohort, will be the true test.

The PDAC complication

On the other side of the pipeline, the original anchor indication - pancreatic cancer - has become more complicated, not easier. Cantargia's nadunolimab was built around a compelling biological story: pancreatic tumors carry KRAS mutations that drive an inflammatory IL-1 signaling pathway, and blocking IL1RAP with nadunolimab interrupts that cycle. The Phase 2 CANFOUR trial presented at ESMO 2024 showed a median overall survival of 13.2 months for nadunolimab plus chemotherapy versus 8.5–9.2 months for chemotherapy alone, with even stronger results (14.2 months) in patients with high tumor IL1RAP expression.

But the PDAC landscape shifted dramatically in April 2026 when Revolution Medicines announced breakthrough Phase 3 data for daraxonrasib, a direct KRAS inhibitor. Daraxonrasib delivered a median overall survival of 13.2 months versus 6.7 months for chemotherapy - a hazard ratio of 0.40, which is remarkable by oncology standards. The data support a New Drug Application submission. If approved, daraxonrasib will redefine the standard of care in previously treated metastatic PDAC.

Cantargia acknowledged the shift bluntly in its Q1 report. Rather than press ahead with the originally planned Phase 2b/3 PDAC study, management is rethinking the timing and structure so that any future pivotal program takes "full advantage of the new RAS inhibitor-driven treatment landscape." In practice, that means nadunolimab will likely need to be evaluated in combination with, or sequenced after, a KRAS inhibitor - not standing alone as it was originally designed to do.

This isn't a death knell. The KRAS-inhibitor era doesn't invalidate the IL1RAP biology; it potentially complements it. But it does add a layer of complexity and time that the market hadn't fully priced into Cantargia's original PDAC timeline. Management has said clarity on the new direction could take "a couple of years." That delay is real, and it's a valid bear argument.

What the numbers say about the risk

The financials are the one place where the setup looks less precarious than the stock price implies. Q1 2026 showed a cash position of SEK 246 million. The rights issue added approximately SEK 75 million. Cantargia's own guidance states that the current cash runway extends into 2028 based on existing commitments, excluding new clinical programs. That's critical context: the company isn't running out of money in the next 12 months, and the rights issue was designed precisely to avoid that scenario.

The enterprise value - market cap minus cash - sits around SEK 182 million. That's the number that represents what the market is actually paying for the pipeline after stripping out the cash on the balance sheet. For a company with a potential milestone pool of up to $613 million from the Otsuka Pharmaceutical acquisition of CAN10, plus a lead oncology program showing 5-for-5 complete remissions in MDS and established Phase 2 activity in pancreatic cancer, the SEK 182 million enterprise value is arguably pricing in a scenario where none of it works.

That doesn't mean it will. It means the downside is capped by the cash balance and the Otsuka milestone floor, while the upside from even a modestly successful MDS program is asymmetric.

What to watch on August 19

The Q2 interim report won't change the fundamental equation. Net sales will remain negligible. The loss will continue. Cash will have declined by another quarter's burn. What matters is three things: (1) any updated commentary on the MDS/AML trial enrollment and preliminary Phase 2a data; (2) whether management clarifies the revised PDAC strategy beyond the "couple of years" timeline already given; and (3) the updated cash runway after a second quarter of spending.

If the MDS enrollment is on track and the safety profile remains acceptable, the thesis strengthens. If management provides a clearer roadmap for combining nadunolimab with KRAS inhibitors in PDAC, the near-term uncertainty around that program eases. If the burn rate has accelerated unexpectedly, the 2028 runway claim needs re-examination.

The posture

I'm not arguing that Cantargia is a sure thing. It isn't. Five patients don't make a program, and the PDAC detour is a real complication. The rights issue's weak subscription suggests existing shareholders are not exactly excited.

But the market's 44% decline over the past year has priced in a near-total loss of optionality across the pipeline, not just the PDAC slowdown. The MDS data, however preliminary, represents an independent value driver that the selloff has ignored. The SEK 182 million enterprise value after cash implies the market thinks the Otsuka milestones won't materialize, the MDS signal won't hold, and the PDAC program will be orphaned by the daraxonrasib approval. That's a sterner verdict than the current evidence supports.

For investors comfortable with clinical-stage biotech risk, the setup offers asymmetric reward. I wouldn't chase it on a post-earnings pop if the MDS news triggers a reflexive rally - the patient count remains too small to justify euphoria. But adding on weakness, or building a position before the August 19 report, captures the disconnect between what the numbers show and what the price reflects.

I'd reassess if the Phase 2a MDS data fails to reproduce the initial response rate, or if the cash runway shortens materially below 2027. Until then, the doomsday narrative has outpaced the evidence.

Don't let this buying opportunity go to waste.